Abstract:Objective To investigate the effects and mechanism of advanced glycation end products(AGEs)on the inflammatory responses of rat vascular adventitial fibroblasts and the interventional effects of candesartan.Methods Isolated vascular adventitial fibroblasts of Sprague-Dawley(SD)rats were cultured.Expression of receptor for advanced glycation end products(RAGE)was examined by reverse transcriptase polymerase chain reaction(RT-PCR)and Western blotting assay.Expression of monoeyte chemoattractant protein(MCP)-1,interleukin(IL)-6,and vascuolar cell adhesion molecule(VCAM)-1 mRNA was also analyzed by RT-PCR.Levels of MCP-1,IL-6,and VCAM-1 in the supernatants were determined by enzyme-linked immunosorbent assay(ELISA).Nuclear factor(NF)-κB and inhibitory protein of NF-κB α(I-κB-α)was analyzed by electrophoretic mobility shift assay(EMSA)and Western blotting.Results AGE-human serum albumin(HSA)(50,100,150,200 and 300 mg/L)up-regulated the expression of RAGE at mRNA and protein levels in a concentration-dependent manner;the expression was significantly higher than those of the control group and HSA group(both P<0.05).The expression of RAGE peaked at the concentration of 200 mg/L,which was significantly higher than that of the other concentration groups(P<0.05).NF-κB transcriptional activity was increased after treatment with AGE-HSA(200 mg/L)for 0.5 h,1.0 h and 2.0 h.Incubation of AFs with AGE-HSA(200 mg/L)for 0.5 h and 1.0 h induced phosphorylation of I-κB-α.AGE-HSA(200 mg/L)treatment increased nuclear NF-κB;candesartan co-treatment inhibited this translocation.I-κB-α phosphorylation in response to AGE-HSA(200 mg/L)was also suppressed by candesartan.AGEs(50,100,200,and 300 mg/L)elevated the mRNA expression of MCP-1,IL-6,and VCAM-1.Compared with control,the expression of IL-6,VCAM-1,and MCP-1 mRNA increased significantly in AGE-HSA 50,100 mg/L groups(P<0.05)and AGE-HSA 200,300 mg/L groups(P<0.01).Pretreatment of the cells with anti-RAGE antibody,MG-132,an inhibitor of NF-κB,and candesartan decreased the AGE-HSA induced expression and supernatant levels of IL-6,VCAM-1,and MCP-1(P<0.05).Conclusion It is indicated that AGEs can increase the expression of MCP-1,IL-6,and VCAM-1 in AFs via RAGE and NF-κB pathways.Candesartan can effectively inhibit phosphorylation of I-κB-α,nuclear translocation of NF-κB and expression of inflammatory factors,suggesting it has a therapeutic effect on vascular complication of diabetes.

Candesartan Inhibits LPS-induced Expression Increase of Toll-Like Receptor 4 and Downstream Inflammatory Factors Likely Via Angiotensin II Type 1 Receptor Independent Pathway in Human Renal Tubular Epithelial Cells.

Candesartan Suppresses Chronic Renal Inflammation by a Novel Antioxidant Action Independent of AT1R Blockade.

Candesartan Reduces the Innate Immune Response to Lipopolysaccharide in Human Monocytes

Candesartan Inhibits Inflammation Through an Angiotensin II Type 1 Receptor Independent Way in Human Embryonic Kidney Epithelial Cells

Candesartan attenuates Angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway.

Abstract 394: Chronic Knockdown of the NTS AT1R Increases Circulating Inflammatory-Endothelial Progenitor Cells Ratio and Exacerbates Hypertension in the SHR

Losartan Reduced Connexin43 Expression in Left Ventricular Myocardium of Spontaneously Hypertensive Rats

The mechanism of anti-inflammation effects by candesartan during inflammation

TLR4/MyD88/NF-κB signaling in the rostral ventrolateral medulla is involved in the depressor effect of candesartan in stress-induced hypertensive rats.

Effects of Candesartan on Insulin Sensitivity and Inflammatory Cytokines in Spontaneously Hypertensive Rats

Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity

Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4+T lymphocytes in Kazakh patients with hypertension from the Xinjiang region

Angiotensin Ⅱ Induces the Release of Inflammation Factors Via TLR4-MyD88 Pathway in Rat Tubular Epithelial Cells

Candesartan Attenuates Hypertension-Associated Pathophysiological Alterations in the Gut

Inhibitory Effect of Losartan on Monocytic Activation via Downregulation of Monocyte Chemoattractant Protein-1 Receptor Expression

Losartan inhibits LPS + ATP-induced IL-1beta secretion from mouse primary macrophages by suppressing NALP3 inflammasome.

Candesartan modulates microglia activation and polarization via NF-κB signaling pathway

Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation

Angiotensin II AT1 Receptor Blockade Ameliorates Brain Inflammation.

Advanced glycation end products enhance inflammatory response of vascular adventitial fibroblasts and effect of candesartan

Losartan Inhibits Conventional Dendritic Cell Maturation And Th1 And Th17 Polarization Responses: Novel Mechanisms Of Preventive Effects On Lipopolysaccharide-Induced Acute Lung Injury